Filing Analysis
Neuronetics, Inc. announced the conclusion of Francis X. Brown III's term as interim principal financial and accounting officer following the appointment of Nir Naor to the role. Mr. Brown will remain with the company in a consulting capacity.
🚩 Red Flags
- Transition from interim to permanent CFO/Principal Financial Officer can sometimes indicate a period of organizational restructuring, though not explicitly stated here.
📋 Key Facts
- Francis X. Brown III's term as interim principal financial and accounting officer ended on August 11, 2026.
- Nir Naor was appointed Executive Vice President, CFO, and Treasurer effective July 23, 2026.
- Nir Naor was appointed principal financial and accounting officer on August 12, 2026.
- Mr. Brown will continue to serve the company as a consultant.
- The company explicitly stated the departure of the interim officer was not due to any dispute or disagreement regarding operations, policies, or practices.
Neuronetics, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2026, and provided a supplemental investor presentation.
🚩 Red Flags
- Explicit mention of 'ability to continue as a going concern' in the safe harbor risk disclosures, indicating ongoing concerns regarding self-sustainability and cash flow.
- Risk factors include ability to achieve positive cash flows and maintaining an existing cash balance.
📋 Key Facts
- Company released financial results for Q2 and H1 2026 on August 11, 2026.
- The filing includes an investor presentation (Exhibit 99.2) under Regulation FD disclosure.
- Management highlighted risks related to the transaction with Greenbrook TMS Inc.
Neuronetics, Inc. announced the departure of its EVP and Chief Legal Officer W. Andrew Macan via a separation agreement effective August 15, 2026. Simultaneously, the company appointed Nir Naor as the new Executive Vice President and CFO, effective July 23, 2026.
🚩 Red Flags
- Succession of key executive roles (CLO and CFO) occurring simultaneously may indicate internal restructuring or transition volatility.
📋 Key Facts
- W. Andrew Macan to depart as EVP, Chief Legal Officer, and Corporate Secretary on August 15, 2026.
- Macan's separation includes a $231,750 retention bonus and a $475,087.50 separation payment paid over 12 months.
- Nir Naor appointed as EVP and CFO effective approximately July 23, 2026.
- Naor's compensation includes a $480,000 base salary and a grant of 500,000 Restricted Stock Units (RSUs) vesting over four years.
- The company stated Macan's departure is not due to any dispute or disagreement with management or the Board.
Neuronetics, Inc. announced the promotion of Cory Anderson from Senior Vice President, Chief Technology Officer to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026.
🚩 Red Flags
- None identified; this is a standard internal promotion.
📋 Key Facts
- Cory Anderson promoted to EVP, General Manager of Greenbrook effective July 1, 2026.
- Annual base salary increased to $425,000.
- Target discretionary annual cash bonus set at 45% of base salary.
- Mr. Anderson has been with the company in various R&D and clinical leadership roles since March 2021.
Neuronetics, Inc. reported the results of its Annual Meeting of Stockholders held on May 28, 2026. The company successfully elected its board of directors, ratified its accounting firm, approved executive compensation, and passed a new equity incentive plan.
📋 Key Facts
- Annual Meeting held on May 28, 2026, with 80.41% of outstanding shares represented (55,950,118 shares).
- All director nominees were elected for one-year terms.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- The 2026 Equity Incentive Plan was approved by stockholders.
- Executive compensation for 2025 was ratified on a non-binding advisory basis.
Neuronetics, Inc. entered into an Amended and Restated Consulting Agreement with its Interim Principal Financial and Accounting Officer, Francis X. Brown III. The agreement clarifies his ongoing service until a permanent controller and PAO are hired, and updates his compensation to $26,000 per month.
🚩 Red Flags
- The company lacks a permanent, full-time controller and a permanent principal financial and accounting officer, relying instead on interim consulting services.
📋 Key Facts
- Agreement dated May 18, 2026, amends the prior consulting agreement with Interim PAO Francis X. Brown III.
- Mr. Brown will continue as Interim PAO until the company hires a full-time controller and a full-time principal financial and accounting officer.
- Compensation is updated to $26,000 per month, replacing the previous fixed hourly rate structure.
Neuronetics, Inc. reported its first quarter 2026 financial results and released an updated investor presentation. The filing highlights the company's ongoing focus on its NeuroStar Advanced Therapy System and mentions risks associated with a transaction involving Greenbrook TMS Inc.
🚩 Red Flags
- History of operating losses and uncertainty regarding the ability to achieve or sustain profitable operations.
- Concentration risk due to heavy reliance on a single product line (NeuroStar Advanced Therapy System).
- Potential integration or execution risks related to the Greenbrook TMS Inc. transaction.
📋 Key Facts
- Financial results announced for the three months ended March 31, 2026.
- Investor presentation released on May 5, 2026, for use in upcoming investor meetings.
- The company references a transaction with Greenbrook TMS Inc. as a factor affecting business relationships and operating results.
- Management provided forward-looking guidance for revenue, expenses, and growth for the remainder of fiscal year 2026.
Neuronetics announced the resignation of its CFO after less than a year in the role, alongside a 5% workforce reduction and a consulting agreement with its former CEO. Despite the leadership transition and restructuring, the company reaffirmed its previously issued financial guidance.
🚩 Red Flags
- Rapid CFO turnover: Steven E. Pfanstiel is resigning after approximately 9 months in the position.
- Workforce reduction of 5% suggests immediate pressure to reduce operating expenses.
- Multiple material 8-K items (1.01, 2.05, 5.02) filed simultaneously, indicating significant corporate upheaval.
📋 Key Facts
- CFO Steven E. Pfanstiel is resigning effective May 1, 2026, having only served since July 15, 2025.
- The company initiated a 5% workforce reduction on April 2, 2026, to optimize its cost structure.
- Restructuring is expected to cost $0.2 million in Q2 2026 but yield $2.5 million to $3.0 million in annualized savings.
- Former CEO Keith J. Sullivan entered into a consulting agreement through March 31, 2027, allowing continued equity vesting.
- The company reaffirmed financial guidance originally provided on March 17, 2026.
Neuronetics, Inc. appointed Daniel L. Reuvers as President and CEO, effective March 23, 2026, while simultaneously reporting its Q4 and full-year 2025 financial results. Mr. Reuvers, a veteran healthcare executive, succeeds the previous leadership with a compensation package including a $730,000 base salary and 1.5 million restricted stock units.
🚩 Red Flags
- Safe harbor language explicitly mentions risks regarding 'self-sustainability and existing cash balances' and a 'history of losses'.
- Multiple 8-K items (2.02, 5.02, 7.01) filed in a single report, often indicating a period of significant transition or stress.
📋 Key Facts
- Daniel L. Reuvers appointed as President and CEO effective March 23, 2026.
- Mr. Reuvers previously served as CEO of Tactile Medical (Nasdaq: TCMD) and EVP at Integra LifeSciences (Nasdaq: IART).
- Compensation includes an annual base salary of $730,000 and a discretionary bonus target of 100%.
- Equity incentive consists of 1,500,000 RSUs, with 500,000 vesting annually over three years.
- The company reported financial results for the fiscal year ended December 31, 2025, on the same day.
- Safe harbor language highlights risks regarding the company's 'history of losses' and 'self-sustainability'.
Neuronetics, Inc. entered into a Second Amendment to its Registration Rights Agreement with Madryn Asset Management. The amendment mandates the filing of a resale registration statement for Madryn's shares following the 2025 10-K and requires Madryn to vote its shares in accordance with Board recommendations at the 2026 annual meeting.
🚩 Red Flags
- The agreement includes a voting commitment, requiring a major shareholder to vote with the Board, which can be a sign of management entrenchment
- This is the second amendment to the registration rights, suggesting potential friction or ongoing negotiations regarding liquidity for this major holder
📋 Key Facts
- Second Amendment to Registration Rights Agreement executed on March 2, 2026
- Company must file a Registration Statement within five business days after filing its 2025 Annual Report on Form 10-K
- Madryn Parties received 'Consideration Shares' from the previously disclosed Greenbrook TMS Inc. acquisition
- Madryn agreed to vote all shares in accordance with Board recommendations for certain proposals at the 2026 annual meeting
Neuronetics, Inc. disclosed the approval of annual cash incentive compensation awards for its top executive officers for the 2025 performance year. The awards, totaling approximately $649,376, were approved by the Board and Compensation Committee on February 23, 2026.
📋 Key Facts
- President and CEO Keith J. Sullivan was awarded a cash incentive of $412,775.95.
- EVP, CFO, and Treasurer Steven E. Pfanstiel was awarded a cash incentive of $73,216.44.
- EVP, CLO, and Corporate Secretary W. Andrew Macan was awarded a cash incentive of $163,383.75.
- The incentive awards are scheduled to be paid on or about March 13, 2026.
Neuronetics, Inc. has filed an 8-K to furnish preliminary unaudited financial results for the three and twelve months ended December 31, 2025.
🚩 Red Flags
- Risk factors mentioned in safe harbor language include 'ability to achieve or sustain profitable operations due to our history of losses' and concerns regarding 'self-sustainability and existing cash balances'.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Preliminary unaudited financial results were released via press release on February 10, 2026.
- Reporting period covers the three and twelve months ended December 31, 2025.
Neuronetics, Inc. entered into Amendment No. 4 to its existing Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP on January 15, 2026. The amendment primarily modifies the requirements for subsidiaries joining as 'Obligors' and 'Subsidiary Guarantors' under the Perceptive Facility.
🚩 Red Flags
- Ongoing restructuring of debt/guaranty obligations suggests active management of credit facilities which can sometimes precede liquidity tightening, though no specific distress is noted in this filing.
📋 Key Facts
- Amendment No. 4 to Credit Agreement and Guaranty was executed on January 15, 2026.
- The amendment pertains to the existing 'Perceptive Facility' originally entered into on July 25, 2024.
- The modification specifically addresses requirements for subsidiaries acting as Obligors and Subsidiary Guarantors.
- Lenders include Perceptive Credit Holdings IV, LP acting as collateral agent.
The Company announced the approval of significant cash awards and Restricted Stock Unit (RSU) incentive compensation for its CFO and General Counsel. These awards are designed to incentivize retention, with vesting scheduled for June 30, 2027.
🚩 Red Flags
- None identified; the filing describes retention incentives rather than departures.
📋 Key Facts
- Date of event: December 30, 2025
- CFO Steven E. Pfanstiel awarded $240,000 in cash and 170,212 RSUs.
- General Counsel W. Andrew Macan awarded $231,750 in cash and 164,361 RSUs.
- Incentive awards vest on June 30, 2027, or upon termination without cause.
Neuronetics, Inc. announced the planned retirement of its President and CEO, Keith J. Sullivan, effective June 30, 2026. The company has initiated a search for a successor and noted that the departure is not due to any disagreement with management or the Board.
🚩 Red Flags
- Leadership transition in a micro-cap/small-cap environment can introduce strategic uncertainty.
- Forward-looking statements highlight risks regarding the ability to achieve cash flow breakeven by Q4 2025.
📋 Key Facts
- CEO Keith J. Sullivan will retire on June 30, 2026.
- The Company has commenced a search for a successor.
- Sullivan will remain in his current role until a replacement is hired and will serve as a consultant thereafter to ensure transition.
- The filing also includes the release of Q3 2025 financial results (Item 2.02) and an investor presentation (Item 7.01).
Neuronetics, Inc. has amended its existing credit facility with Perceptive Credit Holdings IV, LP to secure a $10 million loan and issue warrants for 225,000 shares of common stock. The amendment also lowers liquidity requirements through late 2026.
🚩 Red Flags
- Equity dilution via issuance of 225,000 warrants to the lender.
- Continued reliance on debt financing (Perceptive Facility) suggests capital constraints.
- Company's own 'Safe Harbor' statement highlights risks regarding 'ability to achieve and sustain profitable operations due to our history of losses' and 'self-sustainability and existing cash balances'.
📋 Key Facts
- Entered into Amendment No. 3 to the Perceptive Facility on August 1, 2025.
- Permits borrowing of a $10,000,000 Tranche 2A Loan.
- Lowers minimum liquidity balance requirement to $2,000,000 through September 30, 2026.
- Issuance of a Warrant Certificate for 225,000 shares of common stock to Perceptive.
Neuronetics, Inc. announced the appointment of Steven Pfanstiel as Executive Vice President, Chief Financial Officer, and Treasurer, effective July 15, 2025. The company also reaffirmed its previously issued financial guidance for Q2 and full-year 2025.
📋 Key Facts
- Steven Pfanstiel appointed as EVP, CFO, and Treasurer on July 15, 2025.
- Pfanstiel's compensation includes a $480,000 annual base salary and a target discretionary bonus of 50% of base salary.
- Equity incentive: Grant of 400,000 restricted stock units (RSUs) vesting over 3 to 4 years.
- Pfanstiel previously served as CFO/COO at Marinus Pharmaceuticals and held finance roles at LifeScan (Johnson & Johnson subsidiary), OptiNose, and DePuy Synthes.
- The company reaffirmed its financial guidance for Q2 and full-year 2025.
Neuronetics, Inc. held its Annual Meeting of Stockholders on May 22, 2025, reporting the election of directors and ratification of auditors. While most proposals passed, a proposal to amend corporate governance bylaws regarding supermajority voting requirements was defeated.
🚩 Red Flags
- Shareholders rejected an amendment to eliminate supermajority voting requirements, suggesting potential friction or preference for existing governance structures among large shareholders/institutions.
📋 Key Facts
- Annual Meeting held on May 22, 2025, with 81.38% quorum (53,563,675 shares).
- All seven director nominees were elected to one-year terms.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Say-on-pay (Proposal 3) regarding executive compensation was approved by a majority of votes cast.
- Proposal 4 to eliminate supermajority voting requirements in the certificate of incorporation and bylaws was NOT approved.
Neuronetics, Inc. announced the upcoming retirement of CFO Stephen Furlong, effective March 31, 2026. The company is currently conducting a search for a successor and noted that the departure is not due to any disagreement with management or the Board.
🚩 Red Flags
- None identified in this specific filing; departure is planned and non-dispute related.
📋 Key Facts
- CFO Stephen Furlong will retire on March 31, 2026.
- Furlong has served as CFO since 2019.
- The departure is characterized as a retirement and not due to any dispute or disagreement with the Company.
- Furlong will remain in his role until a successor is hired and will serve as an advisor during the transition.
- Company released Q1 2025 financial results (for the period ended March 31, 2025) via press release.
Neuronetics, Inc. filed an 8-K/A to amend its previously released Q4 and full-year 2024 financial results. The amendment is necessitated by non-cash revisions related to the acquisition of Greenbrook TMS Inc. and updates to shares outstanding.
🚩 Red Flags
- Restatement of preliminary financial results originally released on March 4, 2025.
- Accounting complexities arising from the Greenbrook TMS Inc. acquisition requiring post-hoc adjustments.
📋 Key Facts
- Amendment (Form 8-K/A) filed on March 27, 2025, to update previously issued Q4 2024 results.
- Revisions are due to non-cash accounting adjustments following the finalization of audited financial statements for FY 2024.
- Specific drivers for revisions include the acquisition of Greenbrook TMS Inc. and updates to shares outstanding in Q4 2024.
- The company has already filed its Annual Report on Form 10-K, which incorporates these updated figures.
Neuronetics, Inc. filed an 8-K to announce its financial results for the third quarter ended December 31, 2024, and released an investor presentation. The filing includes forward-looking statements regarding the company's path to cash flow positivity.
🚩 Red Flags
- Historical losses mentioned as a risk factor for achieving profitable operations.
- Concentration of revenue among a small number of customers.
- Risks associated with the terms of existing credit facilities.
- Uncertainty regarding self-sustainability and existing cash balances.
📋 Key Facts
- Announced financial results for the three months ended December 31, 2024 (Item 2.02).
- Released a corporate presentation intended for investor use (Item 7.01).
- Management has set a target to achieve cash flow positive in the third quarter of 2025.
- The company is currently executing restructuring plans and managing its 'Better Me Provider' program rollout.
Neuronetics, Inc. announced the approval of annual cash incentive compensation awards for its top executive officers following a meeting of the Board on February 24, 2025.
📋 Key Facts
- The Compensation Committee approved cash incentive awards for CFO Stephen Furlong ($100,794) and General Counsel W. Andrew Macan ($97,313).
- The Board approved a recommended annual cash incentive award for CEO Keith J. Sullivan in the amount of $169,260.
- The awards are scheduled to be paid on or about March 6, 2025.
Neuronetics, Inc. entered into an underwriting agreement to issue 8,000,000 shares of common stock at $2.25 per share, with the underwriter exercising its option for an additional 1,200,000 shares. The offering aims to raise approximately $16.355 million in net proceeds for general corporate purposes.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of up to 9.2 million new shares.
- The offering price of $2.25 may be viewed as a signal of current liquidity needs or downward pressure on share price.
📋 Key Facts
- Offering size: 8,000,000 firm shares plus 1,200,000 option shares (option fully exercised).
- Offering price: $2.25 per share.
- Estimated net proceeds: ~$16.355 million (up to $18.893 million including option shares).
- Underwriter: Canaccord Genuity LLC.
- Expected closing date: February 10, 2025.
- Use of proceeds: Sales and marketing, R&D, potential acquisitions, inventory, working capital, and CAPEX.
The filing is an 8-K/A (amendment) containing a comprehensive list of XBRL taxonomy extensions and financial statement members for Neuronetics, Inc. It appears to be a technical update or correction to previous filings rather than a disclosure of new material events.
🚩 Red Flags
- The filing is an amendment (8-K/A), which often indicates errors in previous disclosures that require correction.
📋 Key Facts
- Filing type is an 8-K/A (amendment to a previously filed 8-K).
- The document contains extensive metadata for financial periods spanning from 2022 through September 30, 2024.
- Includes various debt and equity instruments in the taxonomy: Madryn Credit Facility, Subordinated Convertible Notes, and Secured Promissory Notes.
- Lists multiple related-party entities/individuals including Benjamin Klein and Greybrook Health.
Neuronetics, Inc. issued an 8-K to announce preliminary financial results for the three and twelve months ended December 31, 2024, and provided a strategic investor presentation.
🚩 Red Flags
- Forward-looking statements highlight a history of losses and risks regarding self-sustainability and existing cash balances.
- The company is currently focused on achieving cash flow break-even by Q3 2025, indicating current negative cash flow.
- Risk factors mention revenue concentration among a small number of customers.
📋 Key Facts
- Announced preliminary financial information for the period ending December 31, 2024 (Item 2.02).
- Released a 'Strategic Update January 2025' presentation to investors (Item 7.01).
- The company is working toward achieving cash flow break-even in the third quarter of 2025.
- Management noted ongoing restructuring plans and business integration/effects related to Greenbrook TMS Inc.
Neuronetics, Inc. has completed the acquisition of Greenbrook TMS Inc. via a plan of arrangement effective December 9, 2024. To facilitate this and support post-merger operations, the company amended its credit facility to include a $10 million Tranche 3 loan and increased authorized share count.
🚩 Red Flags
- Increased debt load through the $10M Tranche 3 Loan to fund operations.
- Issuance of warrants (600,000 shares) which may lead to future dilution.
- New net revenue covenants in the amended credit agreement, which could trigger defaults if post-merger integration fails to meet targets.
📋 Key Facts
- Effective date of Greenbrook TMS Inc. acquisition: December 9, 2024.
- Greenbrook shareholders received 0.01021 shares of Neuronetics for each outstanding Greenbrook share.
- Amended Credit Agreement with Perceptive Credit Holdings IV, LP allows for a new $10,000,000 Tranche 3 Loan to finance combined enterprise operations.
- The Amendment includes new net revenue covenants and a Warrant Certificate exercisable into 600,000 shares of common stock.
- Board of Directors expanded from five to seven members with the appointment of Sasha Cucuz and Avinash Amin, M.D.
- Authorized shares increased from 200,000,000 to 250,000,000 via Charter Amendment.
Neuronetics, Inc. filed an 8-K/A to amend a previous filing from November 12, 2024. The amendment serves to clarify the company's financial guidance regarding its path to profitability.
🚩 Red Flags
- Correction of previous financial guidance/press release suggests potential for miscommunication or volatility in investor expectations.
📋 Key Facts
- The filing is an amendment (8-K/A) to a previously filed 8-K dated November 12, 2024.
- Purpose of amendment: To clarify that the Company expects to achieve cash flow breakeven by the third quarter of 2025.
- The filing includes a replacement press release (Exhibit 99.1) containing the corrected guidance.
Neuronetics, Inc. has successfully regained compliance with the Nasdaq minimum bid price requirement of $1.00 per share. The company met the 10-consecutive-business-day closing price threshold on November 11, 2024, effectively resolving the delisting risk previously disclosed in October.
🚩 Red Flags
- Historical non-compliance with Nasdaq's $1.00 minimum bid price rule (previously disclosed Oct 4, 2024).
📋 Key Facts
- The Company received notification from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the 'Bid Price Rule').
- Compliance was achieved by maintaining a closing bid price of $1.00 or more for at least 10 consecutive business days.
- The requirement was officially met on November 11, 2024.
- The delisting matter regarding the minimum bid price is now considered closed.
Neuronetics, Inc. successfully held a Special Meeting of Stockholders where shareholders approved all key proposals related to the acquisition of Greenbrook TMS Inc. The approval includes increasing authorized shares and issuing new shares to complete the arrangement.
🚩 Red Flags
- Low margin of victory on Proposal 3 (Incentive Plan) at only 53.56% approval suggests potential shareholder dissatisfaction or lack of alignment regarding dilution/compensation.
📋 Key Facts
- Special Meeting held on November 8, 2024.
- Proposal 1: Approved amendment to increase authorized common stock from 200,000,000 to 250,000,000 shares (69.38% approval).
- Proposal 2: Approved issuance of Neuronetics Shares to Greenbrook Shareholders per the August 11, 2024 Arrangement Agreement (67.56% approval).
- Proposal 3: Approved increasing the 2018 Equity Incentive Plan reserve by up to 3,500,000 shares (53.56% approval).
- Quorum was met with 24,008,870 shares represented (79.21% of outstanding shares).
Neuronetics, Inc. has implemented a strategic reorganization involving a workforce reduction of approximately 10% to improve operational efficiency and focus on high-growth drivers. The company expects to achieve over $3.5 million in annualized cash savings resulting from this restructuring.
🚩 Red Flags
- Workforce reduction (layoffs) can sometimes indicate underlying pressure on margins or a need for immediate cost-cutting.
📋 Key Facts
- Workforce reduction of approximately 10% implemented on November 8, 2024.
- Anticipated post-reorganization annualized cash savings: >$3.5 million.
- One-time severance and related benefits expense expected: ~$0.4 million.
- The reorganization is intended to sharpen focus on high-growth drivers and improve operational efficiency.
Neuronetics, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024 and provided a supplemental presentation regarding these results.
🚩 Red Flags
- Mention of potential risks related to maintaining Nasdaq listing requirements (noted in safe harbor language).
📋 Key Facts
- Company released Q3 2024 financial results on November 12, 2024.
- A supplemental investor presentation was issued alongside the earnings release.
- The filing includes forward-looking statements regarding a proposed arrangement between Neuronetics and Greenbrook TMS Inc.
Neuronetics, Inc. has amended a Registration Rights Agreement with Madryn Asset Management LP regarding the consummation of its arrangement with Greenbrook TMS Inc. The amendment extends the demand registration period for Consideration Shares from 180 days to 365 days.
🚩 Red Flags
- Potential future dilution: The extension of the demand registration period allows Madryn Parties a longer window (365 days) to register and potentially sell shares, which could create selling pressure on the stock.
📋 Key Facts
- Amendment to the Registration Rights Agreement between Neuronetics and Madryn Parties.
- The Demand Registration Period is increased from 180 days to 365 days following the consummation of the Arrangement.
- The amendment relates to the registration rights for Consideration Shares received by Madryn Parties upon completion of the Greenbrook TMS merger/arrangement.
Neuronetics, Inc. received a deficiency letter from Nasdaq on October 3, 2024, due to its common stock closing below the $1.00 minimum bid price requirement for the last 30 consecutive business days. The company has until April 1, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Potential for a reverse stock split to regain compliance
- Risk of being moved from the Global Market to the Capital Market if compliance is not met
📋 Key Facts
- Received Nasdaq deficiency letter on October 3, 2024.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid price requirement.
- The company has a 180-day compliance period ending April 1, 2025.
- Compliance can be achieved if the stock closes at $1.00 or more for 10 consecutive business days.
- Failure to comply within the first window may lead to a transfer to Nasdaq Capital Market and a second 180-day compliance period.
Neuronetics, Inc. announced receipt of an interim order regarding its proposed arrangement with Greenbrook TMS Inc. and provided details concerning upcoming shareholder meetings.
🚩 Red Flags
- Transaction involves significant regulatory and legal complexities (interim orders, shareholder votes).
- Potential for management distraction due to the ongoing arrangement/merger process.
📋 Key Facts
- The filing relates to a proposed transaction/arrangement between Neuronetics, Inc. and Greenbrook TMS Inc.
- An interim order has been received in respect of the proposed arrangement.
- Details regarding shareholder meetings related to the transaction are being provided via press release (Exhibit 99.1).
- The company is soliciting material pursuant to Rule 14a-12 under the Exchange Act.
Neuronetics, Inc. filed an 8-K to provide a presentation to investors regarding the proposed transaction/arrangement between Neuronetics and Greenbrook TMS Inc.
🚩 Red Flags
- Significant uncertainty regarding the successful completion of the merger/arrangement with Greenbrook TMS Inc.
- Potential for dilution or stock price volatility depending on the final terms and closing of the transaction.
- Risk factors mentioned include management distraction, regulatory hurdles, and potential failure to achieve expected synergies.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure) and soliciting material under Rule 14a-12.
- The company is presenting materials related to a proposed 'Arrangement' with Greenbrook TMS Inc. ('Greenbrook').
- The presentation includes forward-looking statements regarding combined operations, synergies, regulatory tailwinds, and expected cash balances at closing.
- The transaction involves the satisfaction of various conditions, including stockholder approval from both Neuronetics and Greenbrook.
Neuronetics, Inc. filed an 8-K to disclose a pre-recorded virtual fireside chat with customers held on August 15, 2024. The filing includes the presentation and transcript as exhibits under Regulation FD disclosure.
🚩 Red Flags
- Mention of potential risks regarding the ability to achieve cash flow break-even in Q4 2024 and full-year 2025.
- Risks associated with the proposed combination/arrangement with Greenbrook TMS Inc.
📋 Key Facts
- The company hosted a pre-recorded virtual fireside chat with certain customers on August 15, 2024.
- Exhibits 99.1 and 99.2 contain the presentation and transcript of the event respectively.
- The filing includes safe harbor language regarding forward-looking statements related to a 'Proposed Arrangement' with Greenbrook TMS Inc.
Neuronetics, Inc. is providing notice of its participation in the William Blair 44th Annual Growth Stock Conference on August 14, 2024, where it will present financial and operational outlook information.
🚩 Red Flags
- Forward-looking statements include risks regarding the ability to achieve cash flow break-even in Q4 2024 and full-year 2025.
- Mention of potential termination fees related to the proposed Greenbrook TMS merger.
📋 Key Facts
- Company to present at the William Blair 44th Annual Growth Stock Conference on August 14, 2024.
- Presentation includes financial and operational outlook details (Exhibit 99.1).
- The filing mentions a 'Proposed Arrangement' involving a combination with Greenbrook TMS Inc.
Neuronetics, Inc. has entered into a definitive arrangement agreement to acquire Greenbrook TMS Inc. through a plan of arrangement under the Business Corporations Act (Ontario). The transaction is structured as an all-stock deal where Greenbrook shareholders will hold 43% and Neuronetics stockholders 57% of the combined company.
🚩 Red Flags
- Transaction is subject to significant regulatory and court approvals (Ontario Superior Court).
- Requires consent from existing lenders (Perceptive Credit Holdings LV, LP) under Neuronetics' credit facility.
- Subject to a 'no material adverse effect' clause for both parties.
📋 Key Facts
- Neuronetics to acquire all issued and outstanding common shares of Greenbrook TMS Inc.
- Transaction structure: Plan of Arrangement under the Ontario Business Corporations Act (OBCA).
- Consideration: Issuance of approximately 25,304,971 shares of Neuronetics common stock.
- Ownership split: Combined company expected to be 43% Greenbrook shareholders and 57% Neuronetics stockholders on a fully diluted basis.
- Governance: Post-merger board will have seven directors; five appointed by Neuronetics and two by Madryn Asset Management LP.
- Closing conditions include stockholder/shareholder approval, court orders from Ontario Superior Court, and lender consent from Perceptive Credit Holdings LV, LP.
Neuronetics, Inc. announced its unaudited financial results for the first half of 2024 and disclosed a proposed combination (merger/arrangement) with Greenbrook TMS Inc. The filing also includes forward-looking statements regarding the company's path to cash flow break-even.
🚩 Red Flags
- Significant uncertainty regarding the completion of the proposed combination with Greenbrook TMS Inc.
- Potential termination fees required if the arrangement fails to close.
- Historical history of losses mentioned in risk factors.
- Concentration of revenue among a small number of customers.
📋 Key Facts
- Announced unaudited financial results for the three- and six-month periods ended June 30, 2024.
- Disclosed a 'Proposed Arrangement' to combine with Greenbrook TMS Inc. (Greenbrook).
- The company aims to achieve cash flow break-even in Q4 2024 on a quarterly basis and full-year 2025.
- The Proposed Arrangement is subject to stockholder approval and various closing conditions.
Neuronetics, Inc. announced a definitive arrangement agreement to acquire all issued and outstanding common shares of Greenbrook TMS Inc. via a plan of arrangement. The filing also includes the company's Q2 2024 financial results.
🚩 Red Flags
- The company explicitly mentions risks regarding its 'ability to achieve or sustain profitable operations due to our history of losses'.
- Management notes the risk of 'disruption of management’s attention' due to the transaction.
- Potential for significant decline in stock price if the transaction is not completed.
📋 Key Facts
- Neuronetics will acquire all issued and outstanding common shares of Greenbrook TMS Inc. through an Arrangement Agreement.
- The transaction is structured as a plan of arrangement under the Business Corporations Act (Ontario).
- The company released its financial results for the three months ended June 30, 2024.
- Neuronetics aims to achieve cash flow break-even in Q4 2024 and on a full-year basis in 2025.
Neuronetics, Inc. entered into a new $90 million senior secured credit facility with Perceptive Credit Holdings IV, LP to replace its existing $60 million Solar Facility. The company immediately drew $50 million from the first tranche and issued warrants to Perceptive as part of the consideration.
🚩 Red Flags
- Significant equity dilution via warrants issued to Perceptive (up to 1.46M shares).
- Warrant exercise price is tied to the lower of a 10-day VWAP or a future 10-day VWAP ending Aug 31, 2024, which may favor the lender.
- High prepayment penalties (up to 6%) restrict refinancing flexibility in the short term.
- The facility is secured by 'substantially all assets,' including IP, increasing default risk profile.
📋 Key Facts
- New total credit facility amount: up to $90.0 million via three tranches.
- Immediate drawdown: $50.0 million (Tranche 1) borrowed on July 25, 2024.
- Interest rate: Floating rate of 7.00% + the greater of 4.50% or One-Month Term SOFR.
- Maturity date for all tranches: July 25, 2029.
- Warrants issued: Up to 1,462,500 shares of common stock (Initial Warrant + Tranche 2 contingent warrant).
- Prepayment fees: Ranging from 3% to 6% depending on the timing of repayment within the first four years.
- Collateral: First priority security interest in substantially all assets, including intellectual property.
Neuronetics, Inc. filed an 8-K to announce its participation in the William Blair 44th Annual Growth Stock Conference on June 6, 2024. The company provided a presentation regarding its financial and operational outlook for fiscal year 2024.
🚩 Red Flags
- Forward-looking statements highlight risks regarding the ability to achieve profitable operations due to a history of losses.
- The company explicitly mentions the risk of its 'self-sustainability and existing cash balances'.
📋 Key Facts
- Company presented at the William Blair 44th Annual Growth Stock Conference on June 6, 2024.
- The filing includes an investor presentation (Exhibit 99.1) detailing financial and operational outlook.
- Management expressed a goal to achieve cash flow break-even for Q4 2024 and on a full-year basis in 2025.
Neuronetics, Inc. held its Annual Meeting of Stockholders on May 30, 2024. The filing reports the election of directors and the ratification of several shareholder proposals.
📋 Key Facts
- Annual Meeting held on May 30, 2024, with a quorum representing approximately 77.26% of shares outstanding (23,160,764 shares).
- All five director nominees (Robert A. Cascella, Sheryl L. Conley, Glenn P. Muir, Megan Rosengarten, and Keith J. Sullivan) were elected to one-year terms.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Shareholders approved 'Say on Pay' (Proposal 3) regarding executive compensation for 2023.
- Shareholders voted to approve an annual frequency for future advisory votes on executive compensation (Proposal 4).
Neuronetics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that a press release containing these results was issued on May 7, 2024.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 7, 2024.
- The company is classified as an 'emerging growth company'.
- Financial results were released via press release (Exhibit 99.1).
Neuronetics, Inc. filed an 8-K to provide notice of a Regulation FD disclosure regarding the posting of its May 2024 investor presentation and supplemental financial/operating information on its corporate website.
📋 Key Facts
- The company posted its May 2024 investor presentation to its IR website (http://ir.neuronetics.com).
- Supplemental financial and operating information was also released via the same channel.
- Filing date: May 7, 2024.
Neuronetics, Inc. announced a planned reduction in the size of its Board of Directors from eight to five members following the 2024 Annual Meeting. As part of this restructuring, three directors—John K. Bakewell, Joseph H. Capper, and Dr. Wilfred E. Jaeger—will not stand for reelection.
🚩 Red Flags
- None identified; company explicitly states no disagreements with management/operations.
📋 Key Facts
- Board size reduction: From eight directors to five effective after the 2024 Annual Meeting.
- Departing Directors: John K. Bakewell, Joseph H. Capper, and Dr. Wilfred E. Jaeger.
- The departures are not due to any disagreements with the Company regarding operations, policies, or practices.
- Effective date of departure: Conclusion of the 2024 Annual Meeting.
Neuronetics, Inc. announced supplemental information regarding FDA clearance for its NeuroStar Advanced Therapy. The clearance expands the device's indication to include use as a first-line adjunct treatment for major depressive disorder in adolescent patients aged 15-21.
📋 Key Facts
- FDA has cleared NeuroStar Advanced Therapy for use in adolescent patients (ages 15-21).
- The clearance is specifically for use as a first-line, adjunct treatment for major depressive disorder.
- Announcement date: March 25, 2024.
The filing reports the approval of annual cash incentive compensation awards for the Company's top executive leadership team. The awards were approved by the Board following a recommendation from the Compensation Committee.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- CEO Keith J. Sullivan was approved for an annual cash incentive award of $660,800.
- CFO Stephen Furlong was approved for an annual cash incentive award of $226,341.
- General Counsel W. Andrew Macan was approved for an annual cash incentive award of $206,747.
- The awards were scheduled to be paid on or about March 7, 2024.
Neuronetics, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2023.
📋 Key Facts
- Financial results announced for the periods ending December 31, 2023.
- The filing includes a press release as Exhibit 99.1.
- Company is classified as an emerging growth company.
Neuronetics, Inc. filed an 8-K to disclose the posting of its March 2024 investor presentation and supplemental financial/operating information on its corporate website.
📋 Key Facts
- Company posted a new investor presentation on March 5, 2024.
- Supplemental financial and operating information was made available at http://ir.neuronetics.com.
Neuronetics, Inc. issued an 8-K to announce the release of preliminary financial results for the three and twelve months ended December 31, 2023.
📋 Key Facts
- The filing relates to preliminary financial information for the periods ending December 31, 2023.
- A press release was issued on January 8, 2024, containing these results.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.